Maker of much-debated ALS drug says it may stop selling it after study showed it didn’t work
The U.S. FDA approved Amylyx Pharmaceuticals’ Relyvrio in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS, a fatal muscle-wasting disease.